Brainstorm Cell Therapeutics Inc. (BCLI)
$1.12
$-0.06
(-5.08%)
As on 28-Aug-2026 16:00EDT
Market cap
$12 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
54.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-11.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.7
-
Debt to Equity
0
-
Book Value
$-1.1
-
EPS
$-1
-
Face value
--
-
Shares outstanding
11,034,775
10 Years Aggregate
CFO
$-144.99 Mln
EBITDA
$-162.30 Mln
Net Profit
$-162.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| 102.5 | 12.3 | 77.8 | 60.0 | -64.4 | -53.8 | -29.4 |
|
BSE Sensex*
| -8.6 | -0.7 | 3.5 | -3.0 | 5.9 | 6.4 | 10.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
| -75.6 | -44.3 | -83.4 | -59.0 | -11.6 | 5.7 | 20.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Brainstorm Cell Therapeutics (BCLI)
|
1.1 | 12.4 | 0.9 | -10.5 | -1,129.4 | -- | -- | 54.5 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Brainstorm Cell Therapeutics (BCLI)
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that... leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Read more
-
President & Co-CEO
Mr. Chaim Lebovits
-
President & Co-CEO
Mr. Chaim Lebovits
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Brainstorm Cell Therapeutics (BCLI)
What is the current share price of Brainstorm Cell Therapeutics Inc (BCLI) Today?
The share price of Brainstorm Cell Therapeutics Inc (BCLI) is $1.12 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Brainstorm Cell Therapeutics Inc (BCLI) has given a return of -64.44% in the last 3 years.
What is the current PB & PE ratio of Brainstorm Cell Therapeutics Inc (BCLI)?
Since, TTM earnings of Brainstorm Cell Therapeutics Inc (BCLI) is negative, P/E ratio is not available.
The P/B ratio of Brainstorm Cell Therapeutics Inc (BCLI) is 54.50 times as on 28-Aug-2026, a 952 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.50 |
-0.50 |
2024 |
1.11 |
-1.67 |
2023 |
-0.05 |
-0.17 |
2022 |
-0.17 |
-1.33 |
2021 |
-0.40 |
0.50 |
What is the 52 Week High and Low of Brainstorm Cell Therapeutics Inc (BCLI)?
The 52-week high and low of Brainstorm Cell Therapeutics Inc (BCLI) are Rs 1.69 and Rs 0.46 as of 31-Aug-2026.
What is the market cap of Brainstorm Cell Therapeutics Inc (BCLI)?
Brainstorm Cell Therapeutics Inc (BCLI) has a market capitalisation of $ 12 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Brainstorm Cell Therapeutics Inc (BCLI)?
Before investing in Brainstorm Cell Therapeutics Inc (BCLI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.